Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX)‘s stock had its “buy” rating reiterated by equities research analysts at SunTrust Banks, Inc. in a research note issued on Friday. They currently have a $16.00 price target on the software maker’s stock. SunTrust Banks, Inc.’s price objective points to a potential upside of 23.65% from the company’s previous close.

A number of other analysts have also recently issued reports on MDRX. Piper Jaffray Companies restated a “hold” rating and set a $14.00 price objective on shares of Allscripts Healthcare Solutions in a research report on Friday, July 21st. Maxim Group restated a “buy” rating and set a $16.00 price objective on shares of Allscripts Healthcare Solutions in a research report on Friday, August 4th. Morgan Stanley boosted their price objective on Allscripts Healthcare Solutions from $11.00 to $12.00 and gave the company an “underweight” rating in a research report on Monday, August 7th. Citigroup Inc boosted their price objective on Allscripts Healthcare Solutions from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, August 7th. Finally, Zacks Investment Research upgraded Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $15.13.

Shares of Allscripts Healthcare Solutions (NASDAQ MDRX) opened at $12.94 on Friday. The stock has a market cap of $2.30 billion, a PE ratio of 29.65, a P/E/G ratio of 2.39 and a beta of 1.35. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 1.13.

Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its quarterly earnings data on Thursday, August 3rd. The software maker reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.04). The firm had revenue of $426.10 million for the quarter, compared to the consensus estimate of $424.94 million. Allscripts Healthcare Solutions had a negative net margin of 12.23% and a positive return on equity of 6.44%. The business’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.14 earnings per share. equities analysts forecast that Allscripts Healthcare Solutions will post 0.45 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/04/allscripts-healthcare-solutions-inc-mdrx-receives-buy-rating-from-suntrust-banks-inc.html.

In other news, President Richard J. Poulton sold 15,000 shares of the company’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $13.56, for a total transaction of $203,400.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Brian Farley sold 5,000 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $13.52, for a total value of $67,600.00. Following the transaction, the executive vice president now directly owns 196,607 shares in the company, valued at approximately $2,658,126.64. The disclosure for this sale can be found here. Insiders have sold 35,000 shares of company stock worth $473,800 in the last 90 days. Company insiders own 0.75% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. FDx Advisors Inc. acquired a new position in shares of Allscripts Healthcare Solutions during the third quarter valued at $241,000. Candriam Luxembourg S.C.A. lifted its stake in shares of Allscripts Healthcare Solutions by 28.6% during the third quarter. Candriam Luxembourg S.C.A. now owns 135,000 shares of the software maker’s stock valued at $1,921,000 after acquiring an additional 30,000 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Allscripts Healthcare Solutions by 30.1% during the third quarter. Principal Financial Group Inc. now owns 1,003,690 shares of the software maker’s stock valued at $14,283,000 after acquiring an additional 232,209 shares during the period. Wesbanco Bank Inc. lifted its stake in shares of Allscripts Healthcare Solutions by 13.1% during the third quarter. Wesbanco Bank Inc. now owns 166,981 shares of the software maker’s stock valued at $2,376,000 after acquiring an additional 19,394 shares during the period. Finally, Monarch Partners Asset Management LLC acquired a new position in shares of Allscripts Healthcare Solutions during the third quarter valued at $6,447,000.

About Allscripts Healthcare Solutions

Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.

Analyst Recommendations for Allscripts Healthcare Solutions (NASDAQ:MDRX)

Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.